mGluR5 & GERD

mGluR5 inhibition (ADX10059)
The lower esophageal sphincter is controlled by the vagus nerve, which in turn is controlled by a variety of central and peripheral nervous system mechanisms, including metabotropic glutamate receptor 5 (mGluR5) signaling. Preclinical data suggest that stimulation of mGluR5 secondary to distension of the stomach, for example after eating, drinking or swallowing air, initiates a signaling cascade, via the vagus nerve, that causes the lower esophageal sphincter to open. This is a normal safety mechanism to prevent the stomach from becoming excessively distended and allows air to escape from the stomach through belching.

It is believed that this normal physiological response becomes disordered in patients with GERD, allowing stomach contents to seep into the esophagus. Preclinical models of GERD have shown that inhibition of mGluR5 can prevent inappropriate opening of the lower esophageal sphincter and restore normal sphincter function1. Addex was the first in the world to disclose that mGluR5 inhibition reduced the exposure of the esophagus
to acidity and reduced GERD symptoms in humans.

ADX10059 in GERD
GERD